BIIB 115
Alternative Names: BIIB-115; ION-306Latest Information Update: 20 Oct 2022
At a glance
- Originator Ionis Pharmaceuticals
- Developer Biogen; Ionis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action RNA interference; Survival of motor neuron 2 protein expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Spinal muscular atrophy
Most Recent Events
- 12 Oct 2022 Biogen plans a phase I trial in Spinal muscular atrophy (In vounteers) (Intrathecal, Injection) in October 2022 (NCT05575011) (EudraCT2022-000956-12)
- 10 Oct 2022 Phase-I clinical trials in Spinal muscular atrophy (In volunteers) in Netherlands (Intrathecal) (NCT05575011) (EudraCT2022-000956-12)
- 04 Jan 2022 BIIB 115 licensed to Biogen worldwide for the treatment of spinal muscular atrophy